Mark R. Somerfield
American Society of Clinical Oncology
160 Papers
1K Citations
Mark R. Somerfield is an academic researcher from American Society of Clinical Oncology. The author has contributed to research in topics: Guideline & Medicine. The author has an hindex of 64, co-authored 139 publications. Previous affiliations of Mark R. Somerfield include Oregon Health & Science University & Dalhousie University.
Chat about Author
Papers
American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer
J. Douglas Rizzo,Melissa C. Brouwers,Patricia Hurley,Jerome Seidenfeld,Mark R. Somerfield,Sarah Temin +5 more
TL;DR: This guideline update addresses two clinical questions: What are the defining features of patients with a malignancy who are appropriate candidates for ESA treatment and what are the optimal approaches to ESA therapy.
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline
Neelima Denduluri,Mark R. Somerfield,Andrea Eisen,Jamie N. Holloway,Arti Hurria,Tari A. King,Gary H. Lyman,Ann H. Partridge,Melinda L. Telli,Maureen E. Trudeau,Antonio C. Wolff +10 more
TL;DR: A Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer including adjUvant targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancers was identified for adaptation.
135
Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
Barnett S. Kramer,Karen L. Hagerty,Stewart Justman,Mark R. Somerfield,Peter C. Albertsen,William J. Blot,H. Ballentine Carter,Joseph P. Costantino,Jonathan I. Epstein,Paul A. Godley,Russell P. Harris,Timothy J Wilt,Janet Wittes,Robin Zon,Paul Schellhammer +14 more
TL;DR: An evidence-based guideline on the use of 5-alpha-reductase inhibitors (5-ARIs) for prostate cancer chemoprevention and a reduction of approximately 50% in PSA by 12 months is expected in men taking a 5-ARI is developed.
123
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Harold J. Burstein,Mark R. Somerfield,Debra L. Barton,Ali Dorris,Lesley Fallowfield,Dharamvir Jain,Stephen R. D. Johnston,Larissa A. Korde,Jennifer K. Litton,Erin Macrae,Lindsay L. Peterson,Praveen Vikas,Rachel L. Yung,Hope S. Rugo +13 more
TL;DR: In this paper, the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline was updated and an Expert Panel conducted a systematic review.
120